Phase 1b Pilot Study of Atibuclimab (IC14) for Treatment of ST-Elevation Myocardial Infarction
Latest Information Update: 01 Apr 2026
At a glance
- Drugs Atibuclimab (Primary)
- Indications Myocardial infarction
- Focus Adverse reactions
- Sponsors Implicit Bioscience
Most Recent Events
- 27 Mar 2026 Planned primary completion date changed from 1 Mar 2026 to 1 Jun 2026.
- 27 Mar 2026 Status changed from recruiting to active, no longer recruiting.
- 25 Jul 2025 Planned End Date changed from 1 Jun 2026 to 1 Sep 2026.